Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENvue Medical, Inc.NAOV · Entity 8385 | Director · Chief Executive Officer | December 30, 2024 | January 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENvue Medical, Inc.
Report date December 30, 2024 · Filed January 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2034-12-30 | Direct | 80,000 |
Reported balance
After 2024-12-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-30 · Grant · Acquired 80,000 · Balance 80,000 F1: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2024 Filed Jan 3, 2025 16:05 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 80,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001493152-25-000235 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2034-12-30 F1 · derivative.exercise_date: 100% of the options vested on the date of grant in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2024 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 6, 2023 16:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $20.20 | $0.00 |
DisclosureSEC source: 0001493152-23-043893 · ownership.xml · derivative · entry 5 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-12-29 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations F4 · derivative.exercise_date: 25% of the option vested on December 29, 2021 (the " 2021 Date of Grant"), with an additional 25% vested on the three-month anniversary of the 2021 Date of Grant, a further 25% vested on the six-month anniversary of the 2021 Date of Grant, and the final 25% vested on the nine-month anniversary of the 2021 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 6, 2023 16:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $16.80 | $0.00 |
DisclosureSEC source: 0001493152-23-043893 · ownership.xml · derivative · entry 4 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-12-22 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations F3 · derivative.exercise_date: 20% of the option vested on December 22, 2020 (the "2020 Date of Grant"), with an additional 20% vested on the three month anniversary of the 2020 Date of Grant, a further 20% vested on the six month anniversary of the 2020 Date of Grant, a further 20% vested on the nine month anniversary of the 2020 Date of Grant, and the final 20% vested on the year anniversary of the 2020 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| November 29, 2023 Filed Dec 6, 2023 16:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,500 | $0.00 Strike: $14.10 | $0.00 |
DisclosureSEC source: 0001493152-23-043893 · ownership.xml · derivative · entry 3 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2030-10-01 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations Read SEC document |
| November 29, 2023 Filed Dec 6, 2023 16:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,875 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001493152-23-043893 · ownership.xml · derivative · entry 2 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,875 shares Expires 2028-08-14 F5 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations F2 · derivative.exercise_date: The option vested in two equal installments as follows: (i) 1/2 of the total shares on November 1, 2018, and (ii) 1/2 of the total shares on November 1, 2019. Read SEC document |
| November 15, 2023 Filed Dec 6, 2023 16:45 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001493152-23-043893 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-11-15 F1 · derivative.exercise_date: 100% of the option vested on November 15, 2023, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| December 29, 2021 Filed Jan 3, 2022 13:47 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001493152-22-000078 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-12-28 F1 · derivative.exercise_date: The option vests in 12 equal installments on each three-month anniversary of the grant date (December 29, 2021), in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. Read SEC document |
| December 22, 2020 Filed Dec 23, 2020 18:50 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-20-024276 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-12-22 F1 · derivative.exercise_date: 20% of the option vested on December 22, 2020 (the "Date of Grant"), with an additional 20% to vest on the three month anniversary of the Date of Grant, a further 20% to vest on the six month anniversary of the Date of Grant, a further 20% to vest on the nine month anniversary of the Date of Grant, and the final 20% to vest on the year anniversary of the Date of Grant. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 17:56 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001493152-20-020493 · ownership.xml · derivative · entry 2 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2028-08-14 F2 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. F3 · derivative.exercise_date: The option vested in two equal installments as follows: (i) 1/2 of the total shares on November 1, 2018, and (ii) 1/2 of the total shares on November 1, 2019. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 17:56 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | Disposition to issuerOption to Purchase Common Stock · Derivative | 183,359 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001493152-20-020493 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183,359 shares Expires 2026-11-14 F2 · price: The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations. F1 · derivative.exercise_date: On November 14, 2016, the reporting person was granted an option to purchase shares of common stock outside the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. The option vested or vests, as applicable, in four installments as follows: (i) 1/4 of the total shares (rounded down for fractional shares) on the first anniversary of the grant date, (ii) 1/4 of the total shares (rounded down for fractional shares) on the second anniversary of the grant date, (iii) 1/4 of the total shares (rounded down for fractional shares) on the third anniversary of the grant date, and (iv) the remaining shares on the fourth anniversary of the grant date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 19:50 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001493152-20-018961 · ownership.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-10-01 F1 · derivative.exercise_date: The option vested on October 1, 2020. Read SEC document |
| August 14, 2018 Filed Aug 16, 2018 16:33 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 75,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001615774-18-008225 · s112125_form4.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-08-14 F1 · derivative.exercise_date: The option vests in two equal installments as follows: (i) 1/2 of the total shares on November 1, 2018, and (ii) 1/2 of the total shares on November 1, 2019. Vesting is subject to the reporting person's continued service to the Issuer. F1 · balance_after: The option vests in two equal installments as follows: (i) 1/2 of the total shares on November 1, 2018, and (ii) 1/2 of the total shares on November 1, 2019. Vesting is subject to the reporting person's continued service to the Issuer. Read SEC document |
| November 14, 2016 Filed Nov 16, 2016 16:12 UTC | ENvue Medical, Inc. NAOV · Entity 8385 | GrantOption to Purchase Common Stock · Derivative | 183,359 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001144204-16-134957 · v453304_4.xml · derivative · entry 1 Murphy Brian M · CIK 0001687795 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,359 Underlying: Common Stock · 183,359 shares Expires 2026-11-14 F1 · derivative.exercise_date: On November 14, 2016, the reporting person was granted an option to purchase shares of common stock outside the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. The option vests in four installments as follows: (i) 1/4 of the total shares (rounded down for fractional shares) on the first anniversary of the grant date, (ii) 1/4 of the total shares (rounded down for fractional shares) on the second anniversary of the grant date, (iii) 1/4 of the total shares (rounded down for fractional shares) on the third anniversary of the grant date, and (iv) the remaining shares on the fourth anniversary of the grant date. Vesting is subject to the reporting person's continued service to the Issuer. F1 · balance_after: On November 14, 2016, the reporting person was granted an option to purchase shares of common stock outside the NanoVibronix, Inc. 2014 Long-Term Incentive Plan. The option vests in four installments as follows: (i) 1/4 of the total shares (rounded down for fractional shares) on the first anniversary of the grant date, (ii) 1/4 of the total shares (rounded down for fractional shares) on the second anniversary of the grant date, (iii) 1/4 of the total shares (rounded down for fractional shares) on the third anniversary of the grant date, and (iv) the remaining shares on the fourth anniversary of the grant date. Vesting is subject to the reporting person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.